aTyr Pharma, Inc.
ATYR
$0.83
$0.011.55%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 190.00K | 190.00K | 0.00 | 0.00 | 235.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 190.00K | 190.00K | 0.00 | 0.00 | 235.00K |
| Cost of Revenue | 60.22M | 61.56M | 54.23M | 52.82M | 54.37M |
| Gross Profit | -60.03M | -61.37M | -54.23M | -52.82M | -54.14M |
| SG&A Expenses | 17.60M | 17.29M | 15.82M | 14.23M | 13.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 77.82M | 78.84M | 70.05M | 67.05M | 68.15M |
| Operating Income | -77.63M | -78.65M | -70.05M | -67.05M | -67.91M |
| Income Before Tax | -74.12M | -75.13M | -66.64M | -63.42M | -64.02M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -74.12 | -75.13 | -66.64 | -63.42 | -64.02 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 5.00K | 5.00K | 5.00K | 4.00K | -1.00K |
| Net Income | -74.12M | -75.12M | -66.64M | -63.41M | -64.02M |
| EBIT | -77.63M | -78.65M | -70.05M | -67.05M | -67.91M |
| EBITDA | -76.96M | -77.98M | -69.36M | -66.35M | -67.21M |
| EPS Basic | -0.80 | -0.83 | -0.80 | -0.81 | -0.87 |
| Normalized Basic EPS | -0.50 | -0.52 | -0.50 | -0.50 | -0.54 |
| EPS Diluted | -0.80 | -0.83 | -0.80 | -0.81 | -0.87 |
| Normalized Diluted EPS | -0.50 | -0.52 | -0.50 | -0.50 | -0.54 |
| Average Basic Shares Outstanding | 371.77M | 356.48M | 335.13M | 317.30M | 296.89M |
| Average Diluted Shares Outstanding | 371.77M | 356.48M | 335.13M | 317.30M | 296.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |